Published online before print February 3, 2003, doi: 10.1161/01.CIR.0000057545.82749.FF
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;107:798.)
© 2003 American Heart Association, Inc.
Brief Rapid Communications |
Alterations in Janus Kinase (JAK)-Signal Transducers and Activators of Transcription (STAT) Signaling in Patients With End-Stage Dilated Cardiomyopathy
From the Departments of Cardiology and Angiology (E.K.P., D.H.K., A.H., K.C.W., H.D.), and Cardiovascular Surgery (A.L.), Hannover Medical School, Hannover, Germany, and the Institute of Pathophysiology (H.M.), University of Halle-Wittenberg, Germany.
Correspondence to Helmut Drexler, MD, Abt. Kardiologie und Angiologie, Medizinische Hochschule Hannover, Carl-Neuberg Str. 1, 30625 Hannover, Germany. E-mail drexler.helmut{at}mh-hannover.de
Background— Experimental studies indicate that interleukin-6 (IL-6)–related cytokines, signaling via the shared receptor gp130, Janus kinases (JAKs), and signal transducers and activators of transcription (STATs), provide a critical cardiomyocyte survival pathway in vivo. Little is known about the activation of this signaling pathway in the myocardia of patients with end-stage dilated cardiomyopathy (DCM).
Methods and Results— We performed a comprehensive expression and activation analysis of IL-6–related cytokines, receptors, signal transducers, and signal transduction inhibitors in left ventricular (LV) myocardia from patients with DCM (n=10) and non-failing (NF) donor hearts (n=5). Differential expression (DCM versus NF) was observed by immunoblotting at each level of the signaling cascade, including receptor ligands (IL-6: -59%, P<0.01; leukemia inhibitory factor [LIF]: +54%, P<0.05), receptor subunits (LIF receptor: -16%, P<0.05), signaling molecules (the Janus kinase TYK2: -48%, P<0.01; STAT3: -47%, P<0.01), and suppressors of cytokine signaling (SOCS1: +97%, P<0.05; SOCS3: -49%, P<0.01). Tyrosine-phosphorylation status of gp130 was increased (+60%, P<0.05), whereas tyrosine-phosphorylation status of JAK2 was reduced in DCM (-72%, P<0.01). Moreover, as shown by immunohistochemistry, the number of STAT3-positive cardiomyocytes was reduced in DCM (-42%, P<0.01).
Conclusion— Signaling via gp130 and JAK-STAT is profoundly altered in DCM. Importantly, tyrosine-phosphorylation of JAK2 is reduced in the face of increased gp130 phosphorylation, indicating impaired downstream activation of this critical pathway in DCM.
Key Words: cardiomyopathy • interleukins • signal transduction
This article has been cited by other articles:
 |
|
 |
|
  T. Tsoutsman, M. Kelly, D. C.H. Ng, J.-E. Tan, E. Tu, L. Lam, M. A. Bogoyevitch, C. E. Seidman, J.G. Seidman, and C. Semsarian Severe Heart Failure and Early Mortality in a Double-Mutation Mouse Model of Familial Hypertrophic Cardiomyopathy Circulation, April 8, 2008; 117(14): 1820 - 1831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Higuchi, K. Yamauchi-Takihara, G. Matsumiya, N. Fukushima, H. Ichikawa, T. Kuratani, Y. Maehata, and Y. Sawa Granulocyte Colony-Stimulating Factor Prevents Reperfusion Injury After Heart Preservation Ann. Thorac. Surg., April 1, 2008; 85(4): 1367 - 1373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Hilfiker-Kleiner, U. Landmesser, and H. Drexler Molecular Mechanisms in Heart Failure: Focus on Cardiac Hypertrophy, Inflammation, Angiogenesis, and Apoptosis J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A56 - A66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhang, P. Shan, G. Jiang, S. S-M. Zhang, L. E. Otterbein, X.-Y. Fu, and P. J. Lee Endothelial STAT3 is essential for the protective effects of HO-1 in oxidant-induced lung injury FASEB J, October 1, 2006; 20(12): 2156 - 2158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Butler, L. C. Huffman, S. E. Koch, H. S. Hahn, and J. K. Gwathmey STAT-3 activation is necessary for ischemic preconditioning in hypertrophied myocardium Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H797 - H803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Mohri, Y. Fujio, M. Maeda, T. Ito, T. Iwakura, Y. Oshima, Y. Uozumi, M. Segawa, H. Yamamoto, T. Kishimoto, et al. Leukemia Inhibitory Factor Induces Endothelial Differentiation in Cardiac Stem Cells J. Biol. Chem., March 10, 2006; 281(10): 6442 - 6447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Colombo, S. Gatti, F. Turcatti, A. Sordi, L. R. Fassati, F. Bonino, J. M. Lipton, and A. Catania Gene Expression Profiling Reveals Multiple Protective Influences of the Peptide {alpha}-Melanocyte-Stimulating Hormone in Experimental Heart Transplantation J. Immunol., September 1, 2005; 175(5): 3391 - 3401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Ahern, J.-F. Zhang, M. J. Wookalis, and R. Horn Modulation of the Cardiac Sodium Channel NaV1.5 by Fyn, a Src Family Tyrosine Kinase Circ. Res., May 13, 2005; 96(9): 991 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hilfiker-Kleiner, A. Hilfiker, M. Fuchs, K. Kaminski, A. Schaefer, B. Schieffer, A. Hillmer, A. Schmiedl, Z. Ding, E. Podewski, et al. Signal Transducer and Activator of Transcription 3 Is Required for Myocardial Capillary Growth, Control of Interstitial Matrix Deposition, and Heart Protection From Ischemic Injury Circ. Res., July 23, 2004; 95(2): 187 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A.M. Plenz, H. Eschert, M. C. Deng, K. C. Wollert, E. K. Podewski, D. Hilfiker-Kleiner, A. Hilfiker, H. Drexler, A. Lichtenberg, and H. Morawietz What Are Appropriate Controls for Cardiac Interleukin-6 Expression in Heart Failure? * Response Circulation, October 28, 2003; 108 (17): e129 - e130. [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Nathanson An Array of Details on G-Protein Coupled Receptor Signaling: Differential Effects of alpha 1-Adrenergic Receptor Subtypes on Gene Expression and Cytokine Receptor Signaling Mol. Pharmacol., May 1, 2003; 63(5): 959 - 960. [Full Text] [PDF]
|
|